Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham analyst who says the recent FDA approval of MelaFind could push the stock as high as $20 over the next year.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs